In-Depth Analysis, One Drop at a Time: The Liquid Biopsy OncoKit Explained

The Liquid Biopsy OncoKit is engineered specifically for patients affected by lung cancer. Utilizing cutting-edge Next-Generation Sequencing (NGS), the kit is capable of detecting key mutations that are predictive of response to treatment. This enables highly personalized treatment plans and allows for early detection of resistance and relapse.

The beauty of Liquid Biopsy OncoKit lies in its ability to conduct a single test using just a minimal 10 ng of ctDNA, offering a comprehensive snapshot that is crucial for targeted therapy. It can detect mutations that may emerge as resistance mechanisms or through clonal evolution, making it invaluable both for initial diagnosis and monitoring treatment outcomes.

Integrated Features for Comprehensive Analysis

Multi-Gene Sequencing
The kit sequences entire exonic regions of 13 critical genes—ALK, BRAF, EGFR, and so on, giving an in-depth analysis of these critical biomarkers.

Hotspot Regions
It also targets hotspot regions of NTRK1 and NTRK3 to further broaden the spectrum of actionable mutations.

Fusion Gene Capture
For fusion gene identification, all possible rearrangements are covered. The covered intronic regions have been identified through exhaustive literature reviews, ensuring a thorough capture.

Copy Number Variations (CNVs)
Our kit goes beyond mutations and rearrangements. It also detects CNVs across the genome, thanks to a sophisticated low-density SNP array.

The Last Word: How the Liquid Biopsy OncoKit is Changing the Standard of Care

With the Liquid Biopsy OncoKit, we’re not just offering a product; we’re offering a paradigm shift in the way cancer is diagnosed and treated. Our kit combines efficiency, precision, and a comprehensive approach, setting a new benchmark in cancer diagnostics. Isn’t it time you brought this revolutionary technology into your laboratory?

For a future where every second counts, choose precision. Choose the Liquid Biopsy OncoKit.